Related Experiment Videos
[10-year experience with using Cavinton in cerebrovascular disorders]
Insights
Cavinton effectively treats early and chronic cerebrovascular diseases, improving patient status and reducing symptoms in most cases. Its efficacy varies with hemodynamic response in ischemic stroke patients.
Area of Science:
- Neurology
- Pharmacology
- Vascular Medicine
Background:
- Cerebrovascular diseases encompass a range of conditions affecting brain blood supply.
- Effective management of these conditions is crucial for patient outcomes.
- Cavinton has been utilized in clinical practice for cerebrovascular disease treatment.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of Cavinton in patients with various cerebrovascular diseases.
- To identify patient subgroups and hemodynamic profiles that benefit most from Cavinton treatment.
- To determine contraindications for Cavinton use.
Main Methods:
- A retrospective analysis of 967 patients treated with Cavinton over 10 years.
- Assessment of clinical outcomes including subjective status and specific neurological symptoms.
- Evaluation of cerebral hemodynamics using Rheoencephalography (REG) to correlate with treatment response.
Main Results:
- Significant improvement in subjective status and vestibulocerebellar disorders (75-85%) in early and chronic cerebrovascular conditions like neurocirculatory dystonia and circulatory encephalopathy.
- Faster and more pronounced symptom regression in ischemic stroke patients with an adequate hemodynamic response to Cavinton.
- Less favorable outcomes observed in hypertonic and hypotonic hemodynamic types.
- Identified contraindications including severe hypertensive crises and specific cardiac conditions in elderly patients.
Conclusions:
- Cavinton demonstrates significant therapeutic benefits in early and chronic cerebrovascular diseases.
- Treatment response is influenced by the hemodynamic profile of patients, particularly in ischemic stroke.
- Contraindications must be carefully considered to ensure patient safety.
Abstract:
Cavinton was used for 10 years in 967 patients with different cerebrovascular diseases. The highest effect was seen in patients with early forms and primarily chronic forms: vegetovascular (neurocirculatory) dystonia, initial manifestations of brain blood supply insufficiency, circulatory encephalopathy in the first and second stages. Improvement of the subjective status and a decrease of the intensity of vestibulocerebellar disorders were recorded by the end of the treatment in 75-85% of such patients. In ischemic brain stroke, regress of general cerebral and focal symptoms was more rapid and significant in the adequate reaction type of cerebral hemodynamics to cavinton administration (a rise of pulse blood content of the brain and a reduction of the vascular tone according to the REG data) and was less noticeable in the hypertonic and, in particular, in the hypotonic type. Cavinton should not be used in severe general cerebral hypertensive crises, as well as in elderly or senile patients with acute cardio-cerebral or cerebro-cardiac syndrome, postinfarction cardiosclerosis, marked disorders of heart rhythm.